摘要
阿尔兹海默病(AD)是一种病理机制暂不明确的神经退行性疾病,定量药理学中的疾病进展模型可以通过定量的方法充分描述AD患者疾病发展轨迹。通过模型中引入生物标志物信息,可有助于加深对AD病理机制的研究,辅助并优化临床试验的设计。现已有多种经验性或半机制的AD疾病进展模型报道。本文对此进行了综述,以期为阿尔兹海默病的临床研究和新药研发提供参考。
Alzheimer's disease(AD)is a degenerative neurological disease with unclear pathogenesis.The disease progress/trajectory of AD patients can be adequately described by establishing quantitative pharmacological disease progression model.Integrating biomarker information into the model can provide more insight to understand the potential pathological mechanisms and facilitate the optimization of future trial design.Several empirical and semi-mechanism disease progression models have been published.This mini-review is expected to offer some references for the further AD clinical research and new drug development.
作者
张宁远
郑锡军
许羚
刘红霞
郑青山
ZHANG Ningyuan;ZHENG Xijun;XU Ling;LIU Hongxia;ZHENG Qingshan(Drug Clinical Research Center,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Phase Ⅰ Clinical Research Center,Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450000,Henan,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2021年第6期687-694,共8页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
上海市2017年度“科技创新行动计划”项目(17401970900)。
关键词
阿尔兹海默病
疾病进展模型
定量药理学
建模与模拟
Alzheimer's disease
disease progression model
quantitative pharmacology
modeling and simulation